Mission
The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.
About Prostate Cancer
Prostate cancer is the most commonly diagnosed type of cancer for American men, other than skin cancer.
1 in 9 men will be diagnosed with prostate cancer during their lifetime.
Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. About 1 man in 41 will die of prostate cancer.
Prostate cancer is more likely to develop in older men and in African-American men. About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age at diagnosis is about 66.
It is estimated that in 2020, there will be 191,000 new cases of prostate cancer diagnosed and that about 33,000 men will die of the disease.
Statistics from the American Cancer Society.
Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.1 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.
For statistics related to survival, see Survival Rates for Prostate Cancer.
About MPCC
MPCC is a nonprofit organization 501(c)(3) public charity founded in 2001.
MPCC has more than 2000 members and friends of the organization.
MPCC’s board is made up of survivors, medical professionals, representatives of related organizations, and others interested in prostate cancer research, diagnosis, and treatment.
MPCC is guided, in part, by a distinguished Medical Advisory Committee with representatives from leading hospitals and health care providers in the Commonwealth.
MPCC is a participant in the National Alliance of State Prostate Cancer Coalitions (NASPPC).
Board of Directors
Allen L. Snyder III, chairman
Northwestern Mutual
Garth Greimann, secretary & treasurer
Lynn A. Basilio, American Cancer Society
John Carberry, Charles River Mortgage Company, Inc.
Les Cavicchi, Greater Boston Urology, LLC
Jason A. Efstathiou, MD, DPhil, Massachusetts General Hospital
David S. Godkin, Birnbaum & Godkin, LLP
Mark Anthony Hunter, The Goddard School
Robert Kretschmar, Global Capital Resources, Inc.
Tiffany Nagle, Cullari Communications Global
C. Kirk Neison
Avi Nelson
Dalton A. Skerritt, CEHSID
Arnold Barron — emeritus
Neal F. Finnegan — emeritus
Robert S. Lyons — emeritus
Medical Advisory Committee
Richard K. Babayan, MD,
Boston Medical Center
Glenn J. Bubley, MD,
Beth Israel Deaconess Medical Center
J. Jacques Carter, MD, MPH,
Beth Israel Deaconess Medical Center
Jason R. Gee, MD,
Emerson Urology Associates
Adam Kibel, MD,
Brigham and Women’s Hospital
Richard Jaebong Lee, MD,
Massachusetts General Hospital
Paul Nguyen, MD
, Brigham and Women’s Hospital
William U. Shipley, MD,
Massachusetts General Hospital
Mary-Ellen Taplin, MD,
Dana-Farber Cancer Institute
Symposium Planning Committee
Anita Christie,
Massachusetts Department of Public Health
Judy Green,
Massachusetts Prostate Cancer Coalition
Mark Kennedy,
Boston Public Health Commission
Tiffany Nagle,
Cullari Communications Global
Joanne Pokaski,
Beth Israel Deaconess Medical Center
Dalton A. Skerritt,
CEHSID
Allen L. Snyder III,
Northwestern Mutual
William Tinney,
Support Group Leader
Print Page
